


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A compound of the formula (I)



wherein

D is a radical selected from the group comprising heterocyclic and homocyclic rings, X is a radical selected from the group comprising, C=O, SO₂, NH-(C=O), (C=O)-NH, C=S, CH₂, O-(C=O), (C=O)-O, (C=S)-NH, NH-(C=S), NR^a-(C=O), (C=O)-NR^a, (C=S)-NR^a and NR^a-(C=S),

Y is a radical selected from the group comprising -(CH₂)_n-E-(CH₂)_m-L-(CH₂)_k and -(CH₂)_m-L-(CH₂)_k,

wherein E is a radical selected from the group comprising O, S and NR^b,


k, m and n are individually and independently 0, 1, 2 and 3,

Z is a radical selected from the group comprising C=O, and alkyl, whereby preferably alkyl is CH₂ or CH₂CH₂,

A is a radical selected from the group comprising benzyl, substituted benzyl, phenyl, substituted phenyl, alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl,

substituted alkyloxy-cycloalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-aryl, alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl,

B is a radical having formula (II)



wherein

R₁ is selected from the group comprising H, benzyl, substituted benzyl, phenyl, substituted phenyl, alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl, substituted alkyloxy-cycloalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-aryl, alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl,

R₂ is selected from the group comprising H, benzyl, substituted benzyl, phenyl, substituted phenyl, alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl,

alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl, substituted alkyloxy-cycloalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-aryl, alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl,

G is a radical comprising at least one nitrogen atom, and



wherein Q and L are each and independently from each other a radical

selected from the group comprising (C=O)-NH, C=O, C=S, NH, O, S, CH₂, NH-NH, N=N, CH=N, N=CH, NH-(C=O)-NH, NH-(C=O), O-(C=O)-NH, NH-(C=O)-O, (C=O)-O, O-(C=O), NH-(C=S), (C=S)-NH, NH-(C=S)-NH, SO₂, NH-SO₂, SO₂-NH, NR^c, (C=O)-NR^c, NR^c, NR^c-(C=O)-NH, NH-(C=O)-NR^c, NR^c-(C=O)-NR^d, NR^c-(C=O), O-(C=O)-NR^c, NR^c-(C=O)-O, NR^c-(C=S), (C=S)-NR^c, NR^c-(C=S)-NH, NH-(C=S)-NR^c, NR^c-(C=S)-NR^d, NR^c-SO₂ and SO₂-NR^c, and

wherein any of R^a, R^b, R^c and R^d is each and independently a radical selected from the group comprising H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloyl, substituted heterocycloyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl, substituted alkyloxy-cycloalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-aryl, alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl.

2. (Original) The compound according to claim 1, wherein the ring in D is an aromatic or a non-aromatic ring.

3. (Previously Presented) The compound according to claim 1, wherein the ring in D is selected from the group comprising five-membered rings, six-membered rings, seven-membered rings, eight-membered rings, nine-membered rings and ten-membered rings or the ring in D is a condensed ring system selected from the group comprising four-four-membered rings, four-five-membered rings, five-five-membered rings, five-six-membered rings, six six-membered rings, six-seven-membered rings, seven- seven-membered rings.
4. (Previously Presented) The compound according to claim 1, wherein the ring in D is a heterocyclic ring comprising at least one nitrogen atom.
5. (Original) The compound according to claim 4, wherein any of X, Y, Z is attached to the nitrogen atom.
6. (Previously Presented) The compound according to claim 1, wherein the compound is of the formula (III a, III b)




wherein o and p are independently and individually 0, 1, 2 or 3.

7. (Previously Presented) The compound according to claim 1, wherein D is selected from the group comprising pyrrole, pyrrolidine, indole, pyridine, piperidine, quinoline, isoquinoline, imidazole, pyrimidine, purine, pyridazine piperazine, 1,3,5-triazine, 1,2,3-triazole, imidazolidine, and pyrazole and any derivatives of each thereof.

8. (Previously Presented) The compound according to claim 1, wherein D is a radical selected from the group comprising thiophene, thiazole, isothiazole, 1,4 dithiane, 1,3,5 trithiane, and thiomorpholine.
9. (Previously Presented) The compound according to claim 1, wherein D is a radical selected from the group comprising furane, dioxane, pyrane and derivatives of each thereof.
10. (Previously Presented) The compound according to claim 1, wherein D is a radical selected from the group comprising oxazole, isoxazole, and thiazole and derivatives of each thereof.
11. (Previously Presented) The compound according to claim 1, wherein
n is 0, E is O, m is 1, L is (C=O)-NH and k is 0; or
n is 1, E is O, m is 1, L is (C=O)-NH and k is 0; or
n is 0, E is O, m is 2, L is (C=O)-NH and k is 0; or
n is 0, E is CH₂, m is 1, L is (C=O)-NH and k is 0; or
n is 1, E is O, m is 2, L is (C=O)-NH and k is 0.
12. (Previously Presented) The compound according to claim 1, wherein Z is CH₂.
13. (Previously Presented) The compound according to claim 1, wherein A is selected from the group comprising alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl, substituted alkyloxy-cycloalkyl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl.

14. (Previously Presented) The compound according to claim 1, wherein A is selected from the group comprising benzyl, substituted benzyl, phenyl, substituted phenyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, arylalkyl substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-aryl, alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, arylthio-alkyl, substituted arylthio-alkyl, arylthio-cycloalkyl and substituted arylthio-cycloalkyl.


15. (Previously Presented) The compound according to claim 1, wherein A is a phenyl derivative or a benzyl derivative having the formula (IV) or (V)



wherein R₃, R₄, and R₅ is each and independently a radical selected from the group comprising H, halogen, alkyl, substituted alkyl, alkoxy and substituted alkoxy.


16. (Original) The compound according to claim 15, wherein alkyl is selected from the group comprising methyl, ethyl, propyl, butyl, pentyl, hexyl, whereby any of the residues is straight, branched, branched-linear or branched non-linear.

17. (Previously Presented) The compound according to claim 15, wherein alkoxy is selected from the group comprising methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy.
18. (Original) The compound according to claim 15, wherein the substituted alkyl is an alkyl having at least one halogen, NO_2 , OH, CN residue.
19. (Original) The compound according to claim 18, wherein the substituted alkyl is selected from the group comprising CF_3 and CCl_3 .
20. (Previously Presented) The compound according to claim 1, wherein A is a linear alkyl or non-linear alkyl, preferable A is 2,2-dimethyl-butyl.
21. (Previously Presented) The compound according to claim 15, wherein the halogen is independently selected from the group comprising I, Br, Cl and F.
22. (Previously Presented) The compound according to claim 1, wherein R_2 is selected from the group comprising alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl, substituted alkyloxy-cycloalkyl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl, more preferably selected from the group comprising cycloalkyl and substituted cycloalkyl, and more preferably R_2 is



23. (Previously Presented) The compound according to claim 1, wherein R_2 is selected from the group comprising benzyl, substituted benzyl, phenyl, substituted phenyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclalkyl, substituted heterocyclalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-aryl, alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, arylthio-alkyl, substituted arylthio-alkyl, arylthio-cycloalkyl and substituted arylthio-cycloalkyl.

24. (Previously Presented) The compound according to claim 1, wherein R_2 is a radical having the following formula (VI)



wherein q is 0, 1, 2, 3, or 4,

R_6 , R_7 and R_8 are each individually and independently selected from the group of radicals comprising halogen, alkyl, substituted alkyl, alkoxy and substituted alkoxy.

25. (Original) The compound according to claim 24, wherein alkyl and/or the substituted alkyl is selected from the group comprising methyl, ethyl, propyl, butyl,

pentyl, hexyl, whereby any of the residues is straight, branched, branched-linear or branched non-linear.

26. (Previously Presented) The compound according to claim 23, wherein alkoxy is selected from the group comprising methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy.

27. (Previously Presented) The compound according to claim 24, wherein the substituted alkyl is an alkyl having at least one halogen NO₂, OH, CN residue.

28. (Original) The compound according to claim 27, wherein the substituted alkyl is selected from the group comprising CF₃ and CCl₃.

29. (Original) The compound according to claim 24, wherein R₂ is mesitylene.

30. (Previously Presented) The compound according to claim 1, wherein Q of B is C=O.

31. (Previously Presented) The compound according to claim 1, wherein Q of B is SO₂.

32. (Previously Presented) The compound according to claim 1, wherein G is a radical of formula (VII).



wherein R₉ is a heterocyclic ring and r is 0, 1, 2, 3 or 4.

33. (Original) The compound according to claim 32, wherein R_7 is a three-membered, four-membered, five-membered, six-membered, seven-membered, eight-membered, nine-membered or ten-membered ring, preferably having at least one nitrogen atom in the ring.

34. (Original) The compound according to claim 32, wherein R_7 is a condensed ring, preferably having at least one nitrogen atom.


35. (Previously Presented) The compound according to claim 1 wherein G is a guanidine radical.

36. (Previously Presented) The compound according to claim 1, wherein G is $(C=O)-NH_2$ or $NH-(C=O)-NH_2$.

37. (Previously Presented) The compound according to claim 1, wherein G is selected from the group comprising pyridin-2-ylamine, pyrimidin-2-ylamine, 1(2)*H*-imidazol-2-ylamine, 4,5-dihydro-1*H*-imidazol-2-ylamine, 1,4,5,6-tetrahydro-pyrimidin-2-ylamine, 4,5,6,7-tetrahydro-1*H*-[1,3]diazepin-2-ylamine, 1,4,5,6,7,8-hexahydro-[1,3]diazocine, 1,4,5,6,7,8,9,10-octahydro-[1,3]diazecin-2-ylamine, 4,5-dihydro-3*H*-pyrrol-2-ylamine, 3,4,5,6-tetrahydro-pyridin-2-ylamine, 4,5,6,7-tetrahydro-3*H*-azepin-2-ylamine, 3,4,5,6,7,8-hexahydro-azocin-2-ylamine, 3,4,5,6,7,8,9,10-octahydro-azecin-2-ylamine, 1*H*-benzimidazol-2-ylamine, 2(3)*H*-pyrazol-3-ylamine, 1*H*-indol-2-ylamine, 1,2,3,4-tetrahydro-[1,8]naphthyridine, pyrazin-2-ylamine and any derivative of each thereof, whereby preferably such derivative is selected from the group comprising the alkyl derivative, the alkoxy derivative, the thioalkyl derivative and the halogen derivative.


38. (Previously Presented) The compound according to claim 1, wherein G is selected from the group comprising pyridin-2-ylamine, 4-methoxy-pyridin-2-ylamine, 1(2)*H*-imidazol-2-ylamine, 2(3)*H*-pyrazol-3-ylamine.

39. (Previously Presented) A compound having the formula (VIII)



wherein R_{10} is $-\text{CO}-R_{13}$ or $-\text{CO}-\text{O}-R_{13}$,
wherein R_{11} is a substituted pyridine-2-ylamine,
wherein R_{12} is $-\text{CO}-R_{13}$, $-\text{SO}_2-R_{13}$, and
wherein R_{13} is a radical selected from the group comprising alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl,
whereby the compound is preferably a compound according to claim 1.

40. (Currently Amended) The compound according to claim 39, whereby the compound has the formula (IX)



wherein R_{14} is 3,3-dimethyl-butyl or 3-carboxy-phenyl,
wherein R_{15} is pyridin-2-ylamine or 4-methoxy-pyridin-2-ylamine,
wherein R_{16} is $-\text{CO}-R_{17}$, and
wherein R_{17} is mesitylene or 1-methyl cyclohexyl[.].

41. (Original) A compound selected from the group comprising

- compound 5: [2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 9: 2-[1-Phenylacetyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 10: (2-Benzenesulfonylamino-2-carboxy-ethylcarbamoyl)-methoxy-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester)
- compound 13: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid butyl ester
- compound 14: 3-{2-[1-(3-Phenyl-propionyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 15: 3-{2-[1-Phenylmethanesulfonyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic aci
- compound 16: 3-{2-[1-(Butane-1-sulfonyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 17: 3-{2-[1-Methyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 18: 3-{2-[1-(3-Phenyl-propyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 19: 3-{2-[5-(Pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 20: 3-{2-[1-Cyclopentylcarbamoyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 21: 3-{2-[1-Cyclohexylcarbamoyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 22: 3-{2-[1-Butylcarbamoyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 23: 3-{2-[1-Pentylcarbamoyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 24: 3-{2-[1-(2-Fluoro-benzylcarbamoyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 25: 3-{2-[1-(4-Methyl-benzylcarbamoyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 26: 3-{2-[1-Phenethylcarbamoyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 27: 3-{2-[1-(3-Methyl-benzylcarbamoyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 28: 3-{2-[1-Phenylcarbamoyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 29: 3-{2-[1-(2-Methyl-pentanoyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 30: 3-{2-[1-(3-Cyclopentyl-propionyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

- compound 31: 3-{2-[1-(3,3-Dimethyl-butyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 32: 3-{2-[1-Cyclohexanecarbonyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 33: 3-{2-[5-(Pyridin-2-ylaminomethyl)-1-(3,5,5-trimethyl-hexanoyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 34: 3-{2-[5-(Pyridin-2-ylaminomethyl)-1-(2-thiophen-2-yl-acetyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 35: 3-{2-[1-(2-Cyclopentyl-acetyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 36: 3-{2-[1-[2-(3-Methoxy-phenyl)-acetyl]-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 37: 3-{2-[1-Isobutyryl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 38: 3-{2-[1-Propionyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 39: 3-{2-[1-(2-Phenoxy-acetyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 40: 3-{2-[1-Benzoyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 41: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid isobutyl ester

compound 42: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid ethyl ester

compound 43: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid hexyl ester

compound 44: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid prop-2-ynyl ester

compound 45: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid but-3-enyl ester

compound 46: 3-{2-[1-Benzylcarbamoyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 47: 3-{2-[1-Carbamoyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 48: 3-{2-[5-(Pyridin-2-ylaminomethyl)-1-(2-trifluoromethyl-phenylcarbamoyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 49: 3-{2-[1-(Benzo[1,3]dioxol-5-ylcarbamoyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 50: 3-{2-[1-(Biphenyl-4-ylcarbamoyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 51: 3-{2-[1-Benzylthiocarbamoyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

- compound 52: 3-{2-[1-Acetyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 53: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid methyl ester
- compound 54: 3-{2-[1-{2-(2-Methoxy-ethoxy)-acetyl]-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 55: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid 4-fluoro-benzyl ester
- compound 56: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid 4-chloro-benzyl ester
- compound 57: 3-{2-[1-{3-(4-Fluoro-phenyl)-propionyl]-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 58: 3-{2-[1-{3-(4-Chloro-phenyl)-propionyl]-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 59: 4-[[2-Ethoxycarbonyl-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 60: 3-{2-[1-{3,3-Dimethyl-butyl-yl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzoylamino)-propionic acid
- compound 61: 5-[[4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carbothioyl]-amino]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-benzoic acid

- compound 62: 3-{2-[1-(Anthracene-2-sulfonyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 63: 3-{2-[1-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-Pentadecafluoro-octanoyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 64: 3-{2-[1-(3,5-Bis-trifluoromethyl-benzoyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 65: 3-{2-[1-(3,3-Dimethyl-butyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetyl-amino}-2-[(1-methyl-cyclohexanecarbonyl)-amino]-propionic acid
- compound 66: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzoylamino)-ethylcarbamoyl]-methoxy]-2-[(4-methoxy-pyridin-2-ylamino)-methyl]-pyrrolidine-1-carboxylic acid benzyl ester
- compound 67: 4-[[2-(Butane-1-sulfonylamino)-2-carboxy-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 68: 4-[[2-Carboxy-2-phenylmethanesulfonylamino-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 69: 4-[[2-Carboxy-2-methanesulfonylamino-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 70: 4-[[2-Benzoylamino-2-carboxy-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 71: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzoylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 72: 4-[[2-Carboxy-2-phenylacetyl-amino-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 73: 4-({2-[(Biphenyl-4-carbonyl)-amino]-2-carboxy-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 74: 4-{{2-Carboxy-2-(3-phenyl-propionylamino)-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 75: 4-{{2-(3-Butyl-ureido)-2-carboxy-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 76: 4-{{2-Carboxy-2-(3-phenyl-ureido)-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 77: 4-{{2-(3-Benzyl-ureido)-2-carboxy-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 78: 4-({2-Carboxy-2-[3-(2,6-dimethyl-phenyl)-ureido]-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 79: 4-{{2-Carboxy-2-(3-phenethyl-ureido)-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 80: 4-{{2-(3-Biphenyl-4-yl-ureido)-2-carboxy-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 81: 4-[(2-Amino-2-carboxy-ethylcarbamoyl)-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 82: 4-{{2-Carboxy-2-(2,4,6-trimethyl-benzylamino)-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 83: 4-{{2-Carboxy-2-(2-trifluoromethyl-benzoylamino)-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 84: 4-{{2-Carboxy-2-(3-trifluoromethyl-benzoylamino)-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 85: 4-[[2-Carboxy-2-(4-trifluoromethyl-benzoylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 86: 4-[[2-(3,5-Bis-trifluoromethyl-benzoylamino)-2-carboxy-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 87: 4-[[2-Carboxy-2-(2-methyl-benzoylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 88: 4-[[2-Carboxy-2-(2-methoxy-benzoylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 89: 4-[[2-Carboxy-2-(4-methyl-benzoylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 90: 4-[[2-Carboxy-2-(2,6-dimethoxy-benzoylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 91: 4-[[2-Carboxy-2-(cyclohexanecarbonyl-amino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 92: 4-[[2-Carboxy-2-(2,6-dimethyl-benzoylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 93: 4-[[2-Carboxy-2-(3,5-dimethyl-benzoylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 94: 4-[[2-Carboxy-2-(3,4,5-trimethoxy-benzoylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

- compound 95: 4-{{[2-Carboxy-2-(2-fluoro-benzoylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 96: 4-{{[2-Carboxy-2-(2-nitro-benzoylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 97: 4-{{[2-Carboxy-2-(2-chloro-benzoylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 98: 4-{{[2-Carboxy-2-(2,6-dichloro-benzoylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 99: 4-{{[2-Carboxy-2-(2,6-difluoro-benzoylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 100: 4-{{[2-Carboxy-2-[(3-methyl-thiophene-2-carbonyl)-amino]-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 101: 4-{{[2-Carboxy-2-[(1-methyl-cyclohexanecarbonyl)-amino]-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 102: 4-{{[2-Carboxy-2-(3-methyl-2-phenyl-butyrylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 103: 4-{{[2-Carboxy-2-(2-ethyl-benzoylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 104: 4-{{[2-[(Biphenyl-2-carbonyl)-amino]-2-carboxy-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

- compound 105: 4-({2-Carboxy-2-[(2-methyl-cyclohexanecarbonyl)-amino]-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 106: 4-({2-Carboxy-2-[(1-phenyl-cyclopropanecarbonyl)-amino]-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 107: 4-({2-Carboxy-2-[(1-phenyl-cyclopentanecarbonyl)-amino]-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 108: 4-([2-Carboxy-2-(2,2-dicyclohexyl-acetyl-amino)-ethylcarbamoyl]-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 109: 4-([2-Carboxy-2-(2-dimethylamino-benzoylamino)-ethylcarbamoyl]-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 110: 4-([2-Carboxy-2-(2-difluoromethylsulfanyl-benzoylamino)-ethylcarbamoyl]-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 111: 4-([2-Carboxy-2-(2-methyl-pentanoylamino)-ethylcarbamoyl]-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 112: 4-([2-Carboxy-2-(3-cyclopentyl-propionylamino)-ethylcarbamoyl]-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 113: 4-([2-Carboxy-2-(cyclobutanecarbonyl-amino)-ethylcarbamoyl]-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 114: 4-([2-Carboxy-2-(3,3-dimethyl-butyrylamino)-ethylcarbamoyl]-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 115: 4-[[2-Carboxy-2-(3,5,5-trimethyl-hexanoylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 116: 4-[[2-Carboxy-2-propionylamino-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 117: 4-[[2-Carboxy-2-(2,2-dimethyl-propionylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 118: 4-[[2-Carboxy-2-(2,2-dimethyl-butyrylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 119: 4-[[2-Carboxy-2-(cyclopropanecarbonyl-amino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 120: 4-[[2-Carboxy-2-(2-cyclopentyl-acetyl-amino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 121: 4-[[2-Carboxy-2-isobutyrylamino-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 122: 4-[[2-Carboxy-2-(2-cyclohexyl-acetyl-amino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 123: 4-[[2-Carboxy-2-(2-propyl-pentanoylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 124: 4-[[2-Carboxy-2-(4-methyl-pentanoylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 125: 4-[[2-Carboxy-2-(2-cycloheptyl-acetylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 126: 4-[[2-Carboxy-2-(2,4,6-triisopropyl-benzoylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 127: 4-[[2-Carboxy-2-(4-phenyl-butyrylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 128: 4-[[2-Carboxy-2-(5-phenyl-pentanoylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 129: 2-[[1H-Benzoimidazol-2-ylamino)-methyl]-4-[[2-carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-pyrrolidine-1-carboxylic acid benzyl ester

compound 130: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(pyrimidin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 131: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-[(5-chloro-pyridin-2-ylamino)-methyl]-pyrrolidine-1-carboxylic acid benzyl ester

compound 132: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-[(2H-imidazol-2-ylamino)-methyl]-pyrrolidine-1-carboxylic acid benzyl ester

compound 133: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(isoquinolin-3-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 134: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-[(5-trifluoromethyl-pyridin-2-ylamino)-methyl]-pyrrolidine-1-carboxylic acid benzyl ester

compound 135: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-[(1H-pyrazol-3-ylamino)-methyl]-pyrrolidine-1-carboxylic acid benzyl ester

compound 136: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-[(5-methyl-pyridin-2-ylamino)-methyl]-pyrrolidine-1-carboxylic acid benzyl ester

compound 137: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-[(6-methyl-pyridin-2-ylamino)-methyl]-pyrrolidine-1-carboxylic acid benzyl ester

compound 138: 2-[(6-Amino-pyridin-2-ylamino)-methyl]-4-[[2-carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-pyrrolidine-1-carboxylic acid benzyl ester

compound 139: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-[(4,6-dimethyl-pyridin-2-ylamino)-methyl]-pyrrolidine-1-carboxylic acid benzyl ester

compound 140: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(quinolin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 141: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-[(5-phenyl-pyridin-2-ylamino)-methyl]-pyrrolidine-1-carboxylic acid benzyl ester

compound 142: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-[(4-methyl-pyridin-2-ylamino)-methyl]-pyrrolidine-1-carboxylic acid benzyl ester

compound 143: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-[(4-methoxy-pyridin-2-ylamino)-methyl]-pyrrolidine-1-carboxylic acid benzyl ester

compound 144: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-[(4-chloro-pyridin-2-ylamino)-methyl]-pyrrolidine-1-carboxylic acid benzyl ester

- compound 145: 3-(2-{1-(3,3-Dimethyl-butyl)-5-[(4-methoxy-pyridin-2-ylamino)-methyl]-pyrrolidin-3-yloxy}-acetylamino)-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid
- compound 146: 3-(2-{1-(3,3-Dimethyl-butyl)-5-[(4-methoxy-pyridin-2-ylamino)-methyl]-pyrrolidin-3-yloxy}-acetylamino)-2-(2,4,6-trimethyl-benzoylamino)-propionic acid
- compound 147: 4-[(2-Carboxy-2-[(1-methyl-cyclohexanecarbonyl)-amino]-ethylcarbamoyl)-methoxy]-2-[(4-methoxy-pyridin-2-ylamino)-methyl]-pyrrolidine-1-carboxylic acid benzyl ester
- compound 148: 3-(2-{1-(3,3-Dimethyl-butyl)-5-[(4-methoxy-pyridin-2-ylamino)-methyl]-pyrrolidin-3-yloxy}-acetylamino)-2-[(1-methyl-cyclohexanecarbonyl)-amino]-propionic acid
- compound 149: 4-[(1-Carboxymethyl-2-methyl-propylcarbamoyl)-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 150: 4-[(1-Carboxymethyl-2-phenyl-ethylcarbamoyl)-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 151: 4-[(2-Carboxy-1-phenyl-ethylcarbamoyl)-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 152: 4-[(1-Carboxymethyl-2-p-tolyl-ethylcarbamoyl)-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 153: 4-[(2-Carboxy-1-phenyl-ethylcarbamoyl)-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 154: 4-[(3-Carboxy-3-(2,4,6-trimethyl-benzenesulfonylamino)-propylcarbamoyl)-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 155: 4-[(2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethyl)-methyl-carbamoyl)-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester
- compound 156: 4-[(2-Carboxy-2-phenyl-ethylcarbamoyl)-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 157: 4-[[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester.

42. (Previously Presented) Use of a compound according to claim 1 as an inhibitor.
43. (Original) Use according to claim 42, wherein the compound is an inhibitor to an integrin.
44. (Original) Use according to claim 43, wherein the integrin is alpha5beta1 integrin.
45. (Previously Presented) Use of a compound according to claim 1 for the manufacture of a medicament, preferably a medicament for the treatment and/or prevention of a disease.
46. (Original) Use of a compound according to claim 45, wherein the medicament is for a disease mediated by or involving alpha5beta1 integrin.
47. (Previously Presented) Use according to claim 45, wherein the disease is selected from the group comprising diseases based on pathological angiogenesis and/or diseases based on interaction of an integrin with a ligand, whereby preferably the ligand is present on the extracellular matrix and/or on any cell surface.
48. (Previously Presented) Use according to claim 45, wherein the disease is related to an ocular tissue, the skin, joint, neoplasm, synovial tissue, intestinal tissue and/or the bone tissue.

49. (Previously Presented) Use according to claim 45, wherein the disease is a disease of an ocular tissue, preferably diabetic retinopathy, retinopathy of prematurity or macular degeneration, more preferably age related macular degeneration by neovascularization.

50. (Previously Presented) Use according to claim 45, wherein the disease is a disease of the skin, more preferably hemangioma or psoriasis.

51. (Previously Presented) Use according to claim 45, wherein the disease is a disease of or affecting the joints, more preferably rheumatoid arthritis and/or osteoarthritis.

52. (Previously Presented) Use according to claim 45, wherein the disease is a neoplasm, more preferably a malignant neoplasm.

53. (Original) Use according to claim 52, wherein the malignant neoplasm is a carcinoma, more preferably the carcinoma is selected from the group comprising breast carcinoma, ovarian carcinoma, colon carcinoma, pancreatic carcinoma, bladder carcinoma, sarcoma, mesothelioma, teratocarcinoma, astrocytoma, melanoma, angioma and glioblastoma.

54. (Previously Presented) Use according to claim 45, wherein the disease is based on an interaction of an integrin with a ligand in the extracellular matrix or on the cell surface, preferably the disease is an inflammatory disease.

55. (Previously Presented) Use according to claim 45, wherein the disease is based on an interaction of an integrin with a ligand in the extracellular matrix or on the cell surface, preferably the disease is an infectious disease.

56. (Previously Presented) Use according to claim 45, wherein the inflammatory disease is a disease preferably selected from the group comprising gingivitis, inflammatory bowel disease, ulcerative colitis, Crohn's disease and coronary thrombosis.
57. (Previously Presented) Use according to claim 45, wherein the disease is an infectious disease, more preferably the disease is an infection caused by or involving fungi, bacteria and/or viruses.
58. (Previously Presented) Use according to claim 45, wherein the disease is a non-neoplastic cell proliferative disorder, preferably the non-neoplastic cell proliferative disorder is selected from the group comprising fibrotic disorders, more preferably the fibrotic disorder is fibrosis.
59. (Previously Presented) Use according to claim 45, wherein the medicament is for the treatment of macular degeneration, and wherein A is selected from the group comprising alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl, substituted alkyloxy-cycloalkyl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl, substituted alkylthio-cycloalkyl, benzyl, substituted benzyl, phenyl, substituted phenyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-aryl, alkyloxy-heteroaryl, substituted alkyloxy-

heteroaryl, arylthio-alkyl, substituted arylthio-alkyl, arylthio-cycloalkyl and substituted arylthio-cycloalkyl.

60. (Previously Presented) Use according to claim 59, wherein R_2 is selected from the group comprising alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl, substituted alkyloxy-cycloalkyl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl.

61. (Previously Presented) Use according to claim 59, wherein Q of B is C=O or SO₂.

62. (Previously Presented) Use according to claim 45, wherein the medicament is for the treatment of neoplasms, and wherein A is selected from the group comprising alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl, substituted alkyloxy-cycloalkyl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl, benzyl, substituted benzyl, phenyl, substituted phenyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, arylalkyl substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl,

alkyloxy-aryl, substituted alkyloxy-aryl, alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, arylthio-alkyl, substituted arylthio-alkyl, arylthio-cycloalkyl and substituted arylthio-cycloalkyl.

63. (Previously Presented) Use according to claim 45, wherein R_2 is selected from the group comprising benzyl, substituted benzyl, phenyl, substituted phenyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-aryl, alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, arylthio-alkyl, substituted arylthio-alkyl, arylthio-cycloalkyl and substituted arylthio-cycloalkyl.

64. (Previously Presented) Use according to claim 62, wherein Q of B is SO_2 or $C=O$.

65. (Previously Presented) Use of a compound according to claim 39 for the manufacture of a medicament for the treatment of macular degeneration and/or neoplasms.

66. (Previously Presented) Use of a compound according to claim 1 as a diagnostic tool or for the manufacture of a diagnostic tool, whereby preferably such diagnostic tool is useful for *in vivo* and/or for *ex vivo* application.

67. (Previously Presented) Use according to claim 42, wherein the compound comprises a further moiety, preferably a moiety which is selected from the group comprising a targeted moiety, a delivery moiety, and a detection moiety.
68. (Previously Presented) Use according to claim 67, wherein the further moiety is attached, preferably conjugated, to said compound.
69. (Previously Presented) Use according to claim 67, wherein the detection moiety is a label, whereby preferably the label is selected from the group comprising radionuclide labels, paramagnetic material, X-ray attenuating material, immune labels, colored labels, chemiluminescent labels, luminescent labels, fluorescent labels, enzyme substrates, enzymes, and labels complexing detectable ions.
70. (Previously Presented) Use according to claim 67, whereby the diagnostic tool is used in an *in vivo* imaging method and/or an *ex vivo* imaging method, more particularly radionuclide imaging, positron emission tomography, computerized axial tomography, magnetic resonance imaging, luminescence, fluorescence, and chemiluminescence.
71. (Previously Presented) Use according to claim 42, wherein the moiety is a targeted moiety, whereby targeted moiety is preferably a pharmaceutically active moiety, whereby the pharmaceutically active moiety is selected from the group comprising cytotoxins, chemotherapeutics, antibodies, radionuclides and cytotoxic proteins.
72. (Previously Presented) Use according to claim 42, wherein the targeted moiety is selected from the group comprising antibodies, linker molecules and liposomes.

73. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

74. (Original) The pharmaceutical composition according to claim 73 comprising another pharmaceutically active compound.

75. (Previously Presented) The pharmaceutical composition according to claim 73, wherein the compound is present as a pharmaceutically acceptable salt or a pharmaceutically active solvate.

76. (Previously Presented) The pharmaceutical composition according to claim 73, wherein the compound is either alone or in combination with any of the ingredients of the composition present in a multitude of individualised dosages and/or administration forms.

77. (Previously Presented) The pharmaceutical composition according to claim 73 for the treatment of a disease, whereby the disease is selected from diseases mediated by or involving alpha5beta1 integrin.

78. (Previously Presented) The pharmaceutical composition according to claim 73 for the treatment of a disease, mediated by or involving alpha5beta1 integrin.

79. (Cancelled)

80. (Original) The pharmaceutical composition according to claim 79, whereby the method of treatment is selected from the group comprising chemotherapy, anti-hormone therapy, radiation therapy, photodynamic therapy, surgery, and anti-angiogenic therapy.

81. (Previously Presented) A method for treating an integrin associated state in a subject comprising administering to said subject an effective amount of a compound according to claim 1 such that said integrin associated state is treated.

82. (Original) The method according to claim 81, wherein the integrin is alpha5beta1 integrin.

83. (Previously Presented) A method for treating a disease in a subject comprising administering to said subject an effective amount of a compound according to claim 1 such that the disease is treated.

84. (Previously Presented) The method according to claim 83, wherein the disease is mediated by or involving alpha5beta1 integrin.

85. (New) A method of inhibiting angiogenesis in a patient in need of such inhibition, comprising administering to the subject an effective amount of a compound according to claim 1.